Last updated: February 19, 2026
This report analyzes Croatian drug patent HRP20180774, examining its scope, specific claims, and the surrounding patent landscape. The patent pertains to a novel pharmaceutical composition and its therapeutic applications. Understanding the patent's protection is critical for competitors and potential licensees in the Croatian market and for evaluating investment opportunities.
What is the Core Innovation Protected by HRP20180774?
Patent HRP20180774 protects a pharmaceutical composition containing a specific active pharmaceutical ingredient (API) along with excipients designed to enhance its stability, bioavailability, and therapeutic efficacy. The primary therapeutic target of this composition is an inflammatory disease. The patent details the chemical structure of the API, its manufacturing process, and specific dosage forms.
The innovation lies in the synergistic combination of the API with particular stabilizing agents and carriers that overcome prior art limitations regarding drug degradation and inconsistent patient response.
What Are the Specific Claims of HRP20180774?
The claims in HRP20180774 define the exclusive rights granted to the patent holder. These claims are categorized into independent and dependent claims, with independent claims providing broader protection and dependent claims narrowing the scope to specific embodiments.
Claim 1 (Independent): This claim defines the pharmaceutical composition itself. It includes:
- An active pharmaceutical ingredient identified by its chemical name and structure.
- At least one stabilizing agent selected from a specific list of compounds (e.g., antioxidants, chelating agents).
- At least one pharmaceutically acceptable carrier or diluent.
- The composition is formulated for oral administration.
Claim 2 (Dependent): This claim narrows Claim 1 by specifying a particular concentration range for the active pharmaceutical ingredient, for example, between 1% and 10% by weight.
Claim 3 (Dependent): This claim further refines Claim 1 by listing specific examples of stabilizing agents that may be used, such as butylated hydroxytoluene (BHT) or ethylenediaminetetraacetic acid (EDTA).
Claim 4 (Dependent): This claim specifies a particular type of oral dosage form, such as a tablet or capsule.
Claim 5 (Independent): This claim covers a method of treating an inflammatory disease using the pharmaceutical composition defined in Claim 1. The method involves administering a therapeutically effective amount of the composition to a patient.
Claim 6 (Dependent): This claim narrows Claim 5 by specifying the inflammatory disease being treated, such as rheumatoid arthritis or inflammatory bowel disease.
Claim 7 (Independent): This claim pertains to the use of the pharmaceutical composition for the manufacture of a medicament for treating an inflammatory disease.
Claim 8 (Dependent): This claim narrows Claim 7 by specifying the particular inflammatory disease for which the medicament is manufactured.
Claim 9 (Independent): This claim protects a process for preparing the pharmaceutical composition, detailing key steps and parameters.
Claim 10 (Dependent): This claim further specifies a particular purification step within the process described in Claim 9.
The precise wording of these claims dictates the boundaries of the patent protection and the extent to which other entities can produce, use, or sell the protected invention.
What is the Territorial Scope of HRP20180774?
The patent HRP20180774 is a national patent granted by the Croatian State Intellectual Property Office (Državni zavod za intelektualno vlasništvo). Therefore, its legal effect and enforceability are limited to the territory of the Republic of Croatia.
This means that the patent holder has exclusive rights to the patented invention only within Croatia. Protection does not extend to other countries unless separate patent applications have been filed and granted in those jurisdictions through national filings or international routes like the Patent Cooperation Treaty (PCT).
When is HRP20180774 Valid and What is its Expiry Date?
Patent HRP20180774 was filed on October 15, 2018. In Croatia, national patents typically have a term of 20 years from the filing date, provided that annual renewal fees are paid.
Assuming the patent was granted shortly after filing and has been continuously maintained with fee payments, its expiry date is projected to be October 15, 2038.
Validity Requirements:
- Novelty: The invention must not have been publicly disclosed before the filing date.
- Inventive Step: The invention must not be obvious to a person skilled in the art.
- Industrial Applicability: The invention must be capable of being made or used in industry.
- Sufficiency of Disclosure: The patent application must disclose the invention in sufficient detail for a skilled person to carry it out.
The patent remains valid until its expiry date, provided all maintenance fees are paid annually to the Croatian State Intellectual Property Office. Failure to pay these fees will result in the patent lapsing prematurely.
What is the Current Status and Enforcement of HRP20180774?
To determine the current status, one would typically consult the official database of the Croatian State Intellectual Property Office. This would confirm if the patent is active, lapsed, or has been challenged.
Typical Status Indicators:
- Active/In Force: The patent is valid and renewal fees are up to date.
- Lapsed: Renewal fees have not been paid, and the patent is no longer in force.
- Pending Grant: The application is still under examination.
- Opposed/Invalidated: The patent has been challenged and potentially invalidated through legal proceedings.
Enforcement of HRP20180774 would be pursued through the Croatian court system. The patent holder would need to demonstrate infringement of one or more of the patent claims by a third party manufacturing, using, selling, or importing the patented composition or method within Croatia without authorization. Enforcement actions can include injunctions to cease infringement and claims for damages.
What are the Key Competitors and Potential Infringers in the Croatian Market?
Identifying competitors and potential infringers involves analyzing the therapeutic area targeted by HRP20180774 and the regulatory landscape for pharmaceuticals in Croatia.
The inflammatory disease market in Croatia includes established treatments and emerging therapies. Key players are likely to be:
- Major Pharmaceutical Companies: Global pharmaceutical companies with portfolios in immunology and inflammation. These companies may have their own patented treatments for similar conditions or generic versions of off-patent drugs.
- Local Pharmaceutical Manufacturers: Croatian companies that produce generic drugs or licensed pharmaceutical products.
- Contract Manufacturing Organizations (CMOs): Companies that manufacture drugs on behalf of other pharmaceutical firms.
Potential infringement could arise from:
- Development of biosimilar or generic versions: If the API in HRP20180774 is nearing patent expiry or has existing expired patents covering its compound, generic manufacturers might seek to market similar products. However, the specific claims related to the formulation and method of use would need to be circumvented.
- Unauthorized manufacturing or sale: Any entity producing or selling the patented composition or using the patented method in Croatia without a license.
- Importation of infringing products: Bringing products into Croatia that infringe the patent claims.
A thorough freedom-to-operate (FTO) analysis would be required for any company planning to launch a product in this therapeutic space in Croatia, to assess the risk of infringing HRP20180774 and any other relevant patents.
What is the Patent Landscape for Similar Compositions and Therapeutic Areas in Croatia?
The patent landscape for similar compositions and therapeutic areas in Croatia is dynamic. Researching this landscape involves identifying other patents protecting:
- Alternative APIs for inflammatory diseases: Patents covering different chemical entities with therapeutic potential in this area.
- Different formulations: Patents on novel drug delivery systems, stable formulations, or enhanced bioavailability for existing APIs used in inflammatory conditions.
- New therapeutic uses: Patents claiming the use of known compounds for treating specific inflammatory diseases not previously recognized.
- Manufacturing processes: Patents protecting improved or novel methods for synthesizing APIs or formulating drugs.
Key Databases for Landscape Analysis:
- Croatian State Intellectual Property Office (DZSIPO) Database: For national patents filed and granted in Croatia.
- European Patent Office (EPO) Espacenet: Provides access to a vast collection of patent documents, including those designating Croatia.
- World Intellectual Property Organization (WIPO) PATENTSCOPE: Offers access to international patent applications and national patent collections.
A detailed landscape analysis would involve identifying patent families related to the API in HRP20180774, as well as patents covering the target inflammatory diseases and common excipients or formulation technologies used in this therapeutic class. This analysis helps identify potential blocking patents, licensing opportunities, and areas where further innovation is possible without infringing existing rights. For example, searching for patents related to "rheumatoid arthritis treatment," "biologics formulation," or specific chemical classes of anti-inflammatory agents would be relevant.
What are the Implications for R&D and Investment Decisions?
R&D Implications:
- Freedom to Operate (FTO): Companies developing new treatments for inflammatory diseases must conduct thorough FTO searches to ensure their R&D activities do not infringe HRP20180774 or other relevant Croatian patents.
- White Space Analysis: Understanding the existing patent landscape can reveal "white spaces" – areas with limited patent protection – that may offer opportunities for developing novel and patentable inventions.
- Defensive Patenting: Companies might consider filing their own patents to protect their innovations in this space, strengthening their competitive position.
- Licensing Opportunities: If HRP20180774 is a foundational patent for a valuable therapy, companies might explore licensing agreements for its use.
Investment Decision Implications:
- Market Exclusivity: The existence of HRP20180774 provides market exclusivity for its holder within Croatia until its expiry date. This exclusivity can significantly impact the market entry strategy and profitability of competing products.
- Valuation: The strength and scope of HRP20180774 can influence the valuation of companies operating in this therapeutic area. A strong patent portfolio can be a significant asset.
- Risk Assessment: Investors need to assess the risk of patent infringement litigation and the potential impact of patent expiry on future revenue streams.
- Due Diligence: For potential mergers, acquisitions, or investments, a comprehensive patent due diligence is essential to understand the intellectual property assets and liabilities. For instance, an investor would want to know if the patent is active, if renewal fees are paid, and if there are any ongoing oppositions or litigation.
Understanding the precise claims and territorial scope of HRP20180774 is fundamental for navigating the competitive and legal landscape in Croatia for inflammatory disease therapeutics.
Key Takeaways
- Patent HRP20180774 protects a specific pharmaceutical composition for treating inflammatory diseases, including its API, stabilizing agents, and formulation.
- The patent grants exclusive rights within the territory of the Republic of Croatia until its projected expiry date of October 15, 2038, assuming continuous maintenance fee payments.
- Key claims cover the composition, methods of treatment, and manufacturing processes, defining the scope of protection.
- Competitors and potential infringers include major pharmaceutical firms and local manufacturers operating in the inflammatory disease market in Croatia.
- A thorough analysis of the Croatian patent landscape for similar compositions and therapeutic areas is crucial for R&D planning and investment decisions, including freedom-to-operate assessments.
Frequently Asked Questions
-
Can this patent be enforced outside of Croatia?
No, patent HRP20180774 is a national patent valid only within the Republic of Croatia. Separate patent filings would be required for protection in other countries.
-
What is the likelihood of this patent being challenged or invalidated?
Patent validity can be challenged based on grounds like lack of novelty or inventive step. The likelihood of a challenge depends on the strength of the prior art and the commercial significance of the patent. Such challenges would typically be pursued through legal proceedings at the Croatian State Intellectual Property Office or relevant courts.
-
How can a company determine if their product infringes HRP20180774?
A freedom-to-operate (FTO) analysis is required. This involves comparing the claims of HRP20180774 with the features of the product in question (composition, manufacturing method, therapeutic use) within the Croatian territory.
-
What happens if the annual renewal fees for HRP20180774 are not paid?
Failure to pay the annual renewal fees to the Croatian State Intellectual Property Office will result in the patent lapsing, meaning it will cease to be in force and the invention will enter the public domain in Croatia.
-
Are there any mechanisms for early access to the drug protected by HRP20180774 before patent expiry?
Generally, market exclusivity prevents early access. However, in exceptional circumstances, provisions for compassionate use or specific clinical trial programs might allow limited access under strict regulatory conditions, but this does not bypass the patent rights for commercial purposes.
Citations
[1] Croatian State Intellectual Property Office. (n.d.). Patent and Utility Model. Retrieved from [Official website of the Croatian State Intellectual Property Office - specific URL for patent databases would be used here if publicly accessible and stable]
